ustekinumab
ustekinumab is listed in the FDA National Drug Code directory with 37 NDC codes, marketed under brand names including YESINTEK, ustekinumab, STELARA. Available dosage forms: injection, solution, solution.
Drug details
- Generic Name
- ustekinumab
- Brand Names
- YESINTEK, ustekinumab, STELARA, Stelara
- Application Number
- BLA761406
- Sponsor
- Biocon Biologics Inc.
- NDC Codes
- 37
- Dosage Forms
- INJECTION, SOLUTION, SOLUTION
- Routes
- SUBCUTANEOUS, INTRAVENOUS
- Active Ingredients
- USTEKINUMAB
Indications and Usage
1 INDICATIONS AND USAGE STELARA is a human interleukin-12 and -23 antagonist indicated for the treatment of: Moderate to severe plaque psoriasis in adults and pediatric patients 6 years of age and older who are candidates for phototherapy or systemic therapy. ( 1.1 ) Active psoriatic arthritis in adults and pediatric patients 6 years of age and older. ( 1.2 ) Moderately to severely active Crohn's disease in adults and pediatric patients 2 years of age and older. ( 1.3 ) Moderately to severely active ulcerative colitis in adults and pediatric patients 2 years of age and older. ( 1.4 ) 1.1 Plaque Psoriasis (PsO) STELARA is indicated for the treatment of adults and pediatric patients 6 years of age and older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. 1.2 Psoriatic Arthritis (PsA) STELARA is indicated for the treatment of adults and pediatric patients 6 years of age and older with active psoriatic arthritis. 1.3 Crohn's Disease (CD) STELARA is indicated for the treatment of adults and pediatric patients 2 years of age and older with moderately to severely active Crohn's disease. 1.4 Ulcerative Colitis (UC) STELARA is indicated for the treatment of adults and pediatric patients 2 years of age and older with moderately to severely active ulcerative colitis.